Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pharmacologic treatment for intermittent claudication.

Steven M Dean1

  • 1Vascular Services of Ohio, Columbus, OH, USA. sdean1@columbus.rr.com

Vascular Medicine (London, England)
|April 25, 2003
PubMed
Summary

Peripheral arterial disease patients with intermittent claudication have low limb loss risk. Non-interventional therapies, especially pharmacologic agents like Cilostazol, are recommended to improve walking distance and quality of life.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The lipedema common case report form as a research tool: standardizing lipedema data collection.

Frontiers in global women's health·2026
Same author

Images in Vascular Medicine: Madelung disease - A rare fat deposition disorder.

Vascular medicine (London, England)·2023
Same author

Superficial Vein Thrombosis After Intra-articular Particulate Steroid Injection for Knee Osteoarthritis.

American journal of physical medicine & rehabilitation·2023
Same author

Images in Vascular Medicine: A strange case of painful lower-extremity lymphedema, skin thickening, and clubbing related to adenocarcinoma of the lung.

Vascular medicine (London, England)·2023
Same author

The American Venous Forum, American Vein and Lymphatic Society and the Society for Vascular Medicine expert opinion consensus on lymphedema diagnosis and treatment.

Phlebology·2022
Same author

Standard of care for lipedema in the United States.

Phlebology·2021

Area of Science:

  • Vascular Medicine
  • Pharmacology

Background:

  • Peripheral arterial disease (PAD) with intermittent claudication presents a lower risk of limb loss compared to chronic critical limb ischemia.
  • Initial management focuses on conservative, non-interventional therapies over immediate revascularization procedures.

Purpose of the Study:

  • To review pharmacotherapies for improving walking distance in patients with intermittent claudication.
  • To evaluate the efficacy of various drug treatments for PAD symptoms.

Main Methods:

  • Comprehensive literature review of pharmacologic agents investigated for intermittent claudication.
  • Analysis of studies assessing improvements in walking distance and quality of life.

Main Results:

  • Cilostazol (a phosphodiesterase III inhibitor) demonstrated significant benefits in improving walking distance and quality of life.
  • Other agents like propionyl-L-carnitine, oral prostaglandins, L-arginine, and therapeutic angiogenesis show potential.

Conclusions:

  • Pharmacotherapy is a viable option for managing intermittent claudication symptoms when supervised exercise programs are unavailable.
  • Cilostazol is a key pharmacologic treatment for improving function and quality of life in PAD patients with claudication.

Related Experiment Videos